Kairos Pharma reports positive safety results from Phase 2 ENV-105 trial in mCRPC

Kairos Pharma, LTD.

No dose-limiting toxicities or unexpected adverse events in first 10 patients.
No Grade 3 or 4 toxicities observed; side effects manageable with standard care.
Phase 2 trial to enroll 100 patients; interim efficacy data expected September 2025.
Company plans to discuss potential pivotal Phase 3 study design with regulators.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.